| Today’s Big NewsFeb 26, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
| By Kevin Dunleavy At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indianapolis drugmaker said it will begin construction on four new production facilities in the U.S. The effort will more than double what the company has earmarked for domestic drug manufacturing since 2020, bringing the total outlay to more than $50 billion. |
|
|
|
By James Waldron Eikon Therapeutics is no stranger to eye-catching funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials. |
By Conor Hale Kestra's vest-like Assure cardioverter defibrillators have been worn by more than 17,000 patients since its launch in August 2022. It aims to join the Nasdaq under the ticker KTMS. |
By Nick Paul Taylor Arnie told us he’d be back. Three months after becoming Zimmer Biomet’s chief movement officer, the quintessential action hero has returned to front a campaign that puts a twist on his famous "I'll be back" catchphrase to motivate people living with joint pain. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT Softgels have emerged as a versatile dosage form, yet they are often overlooked. This webinar will explore the role of softgels in both early-stage and post-approval lifecycle management strategies. Learn about key considerations for launching with softgels, opportunities for post-approval switches to or from softgels, and how softgels compare to other dose forms. Register now. 
|
|
By Zoey Becker The government price negotiations affecting Keytruda wouldn't take effect until 2028, Merck said in its annual securities filing. That year will also see a key patent loss for the drug. |
By Gabrielle Masson Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease, in a deal worth up to $50 million in biobucks. Since the buy was announced, Organovo’s stock has skyrocketed 244%. |
By Conor Hale The assets from Fresenius’ Spectra Laboratories subsidiary include water purification testing for use in dialysis machines, a new area for Quest. |
By Andrea Park More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo is debuting its first-ever branded TV commercial in the indication. |
By Angus Liu Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought investors’ attention to the company’s appetite in dealmaking. |
By Nick Paul Taylor AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival, its primary endpoint, but is yet to show patients live longer on the drug candidate. |
By Fraiser Kansteiner Following an inspection of Piramal’s production facility in Maharashtra, India, that ran from Feb. 11 to Feb. 17, the FDA slapped the company with six-observation Form 483 detailing shortfalls related to quality control, written records, equipment maintenance and more. The writeup comes after Piramal received a separate Form 483 at a site in Michigan last February. |
By James Waldron The deal will see HBM Alpha Therapeutics, which was formed around Harbour’s antibody expertise, transfer the global rights outside of China for a corticotropin-releasing hormone therapy to an unnamed “business partner.” |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
|
|---|
|
|
|
Tuesday, March 4, 2025 | 2pm ET / 11am PT Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
